“…Reduction/loss of E-cadherin has been associated with the development and progression of human carcinomas, by contributing to tumour invasion and metastases (Charalabopoulos et al, 2002;Hirohashi and Kanai, 2003). Abnormal E-cadherin expression (heterogeneous, cytoplasmic, or absent) has been detected immunohistochemically in a variety of poorly differentiated, invasive and metastatic carcinomas, such as gastric adenocarcinoma, lobular breast carcinoma, colorectal tumours, prostate adenocarcinoma, pancreatic, and bladder cancer (Charalabopoulos et al, 2002(Charalabopoulos et al, , 2004Chang et al, 2002;Hirohashi and Kanai, 2003;Zhang et al, 2004;Massarelli et al, 2005). Regarding testicular neoplasms, there are less than a handful of studies, with conflicting results (Heidenreich et al, 1998;Saito et al, 2000;Honecker et al, 2004).…”